Your browser version may not work well with NCBI's Web applications. More information here...
1: IDrugs. 1998 Nov;1(7):813-7.Links

AD-5423 (Dainippon Pharmaceutical Co Ltd).

Heading CE.

11 Kingsend, Ruislip, Middlesex, HA4 7DD, UK.

AD-5423, a D(2)/5-HT(2) antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other psychoses. In a phase I study of AD-5423 in eight healthy volunteers, it appeared to be well-tolerated and failed to induce extra pyramidal side effects, excessive sedation or hypotension [181465]. Analysts at Yamaichi estimate that AD-5423 will be launched in Japan in 1999 and annual sales will be less than five billion Yen [216018].

PMID: 18465651 [PubMed - in process]